Swiss Pharma Stock News

Straumann Holding (SWX:STMN) announced an increase to its annual dividend alongside the release of its latest full year financial results. The new dividend level reflects the board's current capital allocation decision following the recent earnings announcement. This update adds a fresh data point for investors tracking the company's income profile and cash returns. Straumann Holding's latest dividend move comes after a challenging share price period, with the stock at CHF91.7 and showing a...

Sika (SWX:SIKA) is back in focus after recent share price moves that left the stock about 4.7% lower year to date, despite a roughly 5.8% gain over the past month. See our latest analysis for Sika. The recent 5.8% 30 day share price return contrasts with a year to date share price decline of about 4.7%. At the same time, the 1 year total shareholder return of roughly 31.8% and 5 year total shareholder return of about 32.7% signal fading longer term momentum. If this mixed picture has you...

Amrize (SWX:AMRZ) has drawn fresh attention after issuing upbeat 2026 revenue guidance, outlining both ordinary and special dividend proposals, and attracting supportive analyst commentary following its recent spin off. See our latest analysis for Amrize. After the guidance, dividend proposals and recent board and auditor changes, Amrize’s 7 day share price return of 9.34% and 90 day share price return of 20.79% suggest building positive momentum from a starting point of CHF49.15. If this has...

Alcon (SWX:ALC) is back in focus after the U.S. launch of its TOTAL30 Multifocal for Astigmatism contact lenses, a product aimed at presbyopic patients with astigmatism who have limited soft lens options. See our latest analysis for Alcon. The TOTAL30 Multifocal for Astigmatism launch comes as Alcon’s share price sits at CHF63.78, with a 7 day share price return of 6.1% but a 1 year total shareholder return decline of 20.6%, suggesting recent momentum contrasts with weaker longer term...

Belimo Holding (SWX:BEAN) reported full-year 2025 earnings with sales of CHF 1,120.81 million, net income of CHF 181.63 million, and basic EPS of CHF 14.77 from continuing operations. See our latest analysis for BELIMO Holding. The earnings release and cautious 2026 outlook have coincided with some pressure on the shares, with a 1-day share price return of a 10% decline and a 7-day share price return of a 6.3% decline. At the same time, the 1-year total shareholder return of 36.7% and 5-year...

Event driven repositioning at Partners Group Holding Partners Group Holding (SWX:PGHN) is in focus after shifting capital away from technology and software toward AI linked infrastructure assets, while its open ended private credit funds avoided net redemptions during recent sector volatility. See our latest analysis for Partners Group Holding. The recent repositioning toward AI linked infrastructure comes after a mixed run for investors, with a 30 day share price return of 14.25% decline, a...

Cembra Money Bank AG has already reported its full-year 2025 results, with net interest income of CHF 372.16 million and net income of CHF 179.57 million, and announced an annual dividend of CHF 4.60 per share, ex-date April 28, 2026. While net interest income eased slightly from the prior year, higher net income and an increased dividend highlight the bank’s ability to convert its lending activities into growing shareholder distributions. Next, we’ll examine how the higher net income and...

Why Novartis Stock Is On Investors’ Radar Today Novartis (SWX:NOVN) has drawn fresh attention after recent performance data showed a 9.9% return over the past month and 23% over the past 3 months, prompting investors to reassess its current valuation profile. See our latest analysis for Novartis. Beyond the recent jump, Novartis’ 16.55% year to date share price return and 33.45% one year total shareholder return suggest momentum has been building around its CHF126.46 share price and ongoing...

Nestlé (SWX:NESN) has set out a company wide shakeup, moving to sell its remaining ice cream assets, explore exits from vitamins and waters, and concentrate on coffee, petcare, nutrition, and food and snacks. See our latest analysis for Nestlé. These portfolio moves and the recent earnings update have come alongside a 10.55% 1 month share price return to CHF80.91. The 1 year total shareholder return of a 1.51% decline shows momentum has only recently started to improve after weaker multi year...

Sika (SWX:SIKA) has wrapped up FY 2025 with Q4 revenue of CHF 2.6b and net income of CHF 174.1m, while Q4 basic EPS came in at CHF 1.09. Over the past few quarters, the company has reported revenue of CHF 2.8b and EPS of CHF 2.02 in Q4 2024, CHF 2.9b in Q3 2025, and CHF 2.6b in Q4 2025. This sets up a results season where investors are likely to focus on how these changes in revenue and EPS relate to margins. See our full analysis for Sika. With the latest figures on the table, the next step...

EFG International (SWX:EFGN) has reported its FY 2025 results with second half revenue of CHF 864.5 million and basic EPS of CHF 0.34, alongside net income excluding extra items of CHF 112.8 million. The group has seen revenue move from CHF 753.4 million and basic EPS of CHF 0.49 in the second half of 2024 to CHF 793.8 million and basic EPS of CHF 0.71 in the first half of 2025. Trailing twelve month revenue of CHF 1.66 billion and basic EPS of CHF 1.03 set the broader context for today’s...

CPH Group (SWX:CPHN) has reported fresh numbers for FY 2025, with second half revenue of CHF158.1 million and basic EPS of CHF1.04, alongside trailing 12 month revenue of CHF334.1 million and EPS of CHF3.90 that reflect a very large 402.6% earnings jump over the last year and a net margin that has increased to 7% from 1%. The company has reported revenue rising from CHF146.4 million and EPS of CHF2.23 in the second half of 2024 to CHF175.9 million and EPS of CHF2.85 in the first half of...

Nestlé (SWX:NESN) is overhauling its business under new CEO Philipp Navratil. The company is selling its remaining ice cream operations to Froneri. Nestlé is reorganizing around four divisions: coffee, petcare, nutrition, and food & snacks. A potential sale process has started for its waters and premium beverages segment. Executive changes include Anna Mohl stepping down after Health Science was folded into the new Nutrition division. Nestlé is one of the largest global consumer packaged...

Sunrise Communications (SWX:SUNN) has wrapped up FY 2025 with Q4 revenue of CHF 788.8 million and a net income loss of CHF 50.1 million, while the trailing twelve months show revenue of CHF 2.98 billion alongside a loss of CHF 112.2 million. The company has seen quarterly revenue move in a tight band between CHF 722.1 million and CHF 788.8 million from Q1 to Q4 2025, with basic EPS ranging from a loss of CHF 0.022 in Q1 to a loss of CHF 0.075 in Q3. This keeps the spotlight squarely on when...

If you are wondering whether Novartis shares still offer value at current levels, this article walks through what the numbers say about the price you are paying versus what you are getting. The stock last closed at $126.48, with returns of 2.2% over 7 days, 10.7% over 30 days, 16.6% year to date, 35.5% over 1 year, 85.7% over 3 years and 104.7% over 5 years. This naturally raises questions about how much of the story is already reflected in the price. Recent headlines around Novartis have...

ams-OSRAM (SWX:AMS) has attracted fresh attention after its Open System Protocol for automotive lighting progressed toward ISO standard status, positioning the company more firmly within next generation vehicle electronics architectures. See our latest analysis for ams-OSRAM. That progress toward an ISO standard comes shortly after ams-OSRAM reported 2025 results that showed sales of €3,323m with a net loss of €130m, alongside guidance for first quarter 2026 revenues between €710m and €810m...

Roche Holding (SWX:ROG) reported phase III trial results showing Gazyva achieved statistically significant and clinically meaningful outcomes in primary membranous nephropathy. The company highlighted that Gazyva could become the first therapy specifically indicated for this rare kidney disease, subject to regulatory review and approval. Roche also appointed Mark Dawson as Head of Pharma Research and Early Development, adding a globally recognized cancer researcher to its senior...

Amidst a backdrop of declining U.S. stock indexes and heightened concerns over AI's disruptive potential, the global market landscape remains dynamic, with significant employment gains in the U.S. affecting rate cut expectations and European markets experiencing volatility due to similar AI apprehensions. In this environment, identifying high growth tech stocks with promising global potential requires an understanding of how these companies can navigate current challenges such as...

Cosmo Pharmaceuticals (SWX:COPN) has drawn attention after a strong share price move in recent months, prompting investors to look more closely at how its gastroenterology, dermatology, and healthtech portfolio lines up with current expectations. See our latest analysis for Cosmo Pharmaceuticals. At a share price of CHF122.6, Cosmo Pharmaceuticals has logged a 9.66% 1 month share price return and an 81.90% 3 month share price return. The 1 year total shareholder return of 89.84% suggests...

As European markets experience volatility amid global concerns over AI disruptions, the pan-European STOXX Europe 600 Index has managed to hit new highs, reflecting resilience in the face of these challenges. In this environment, dividend stocks can offer a measure of stability and income potential for investors seeking to navigate uncertain times.

Amrize (SWX:AMRZ) just closed FY 2025 with Q4 revenue of US$2.8b, Basic EPS of US$0.54 and net income of US$298m, while trailing twelve month revenue came in at US$11.8b with Basic EPS of US$2.14 and net income of US$1.2b. The company has seen quarterly revenue move from US$2.1b in Q1 2025 to a peak of US$3.7b in Q3 before Q4’s US$2.8b, with EPS ranging from a Q1 loss of US$0.15 per share to US$0.99 in Q3 and US$0.54 in Q4. This gives investors a full year view of how the earnings power has...

Julius Bär Gruppe (SWX:BAER) is expanding its footprint in India, joining other global financial firms in setting up global capability centres and hiring across cities such as Chennai and Hyderabad. See our latest analysis for Julius Bär Gruppe. At a share price of CHF66.0, Julius Bär Gruppe’s recent India expansion news arrives after a 13.71% 90 day share price return and an 18.79% 1 year total shareholder return. This may indicate that momentum has been building rather than fading. If this...

Basilea Pharmaceutica (SWX:BSLN) has just posted its FY 2025 numbers with first half revenue of CHF103.96 million and basic EPS of CHF1.29, following FY 2024 second half revenue of CHF132.25 million and basic EPS of CHF4.70. The company has seen revenue move from CHF76.29 million in FY 2024 first half to CHF132.25 million in second half and then CHF103.96 million in FY 2025 first half, while basic EPS shifted from CHF1.72 to CHF4.70 and then CHF1.29. This sets up a results picture that puts...

Swiss Prime Site (SWX:SPSN) drew fresh attention after reporting full year 2025 earnings along with a proposed dividend increase to CHF 3.50 per share, with shareholders set to vote at the 12 March 2026 AGM. See our latest analysis for Swiss Prime Site. The proposed dividend increase and solid full year 2025 earnings come after a strong run in the share price, with a 90 day share price return of 17.63%, a 1 year total shareholder return of 29.71% and a 3 year total shareholder return of...